- Home
- MYGN vs NMM Comparison
MYGN vs NMM Comparison
Compare MYGN & NMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- NMM
- Stock Information
- Founded
- MYGN 1991
- NMM 2007
- Country
- MYGN United States
- NMM Greece
- Employees
- MYGN N/A
- NMM N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- NMM Marine Transportation
- Sector
- MYGN Health Care
- NMM Consumer Discretionary
- Exchange
- MYGN Nasdaq
- NMM Nasdaq
- Market Cap
- MYGN 642.0M
- NMM 1.4B
- IPO Year
- MYGN 1995
- NMM 2007
- Fundamental
- Price
- MYGN $7.52
- NMM $48.74
- Analyst Decision
- MYGN Hold
- NMM Strong Buy
- Analyst Count
- MYGN 13
- NMM 1
- Target Price
- MYGN $13.50
- NMM $80.00
- AVG Volume (30 Days)
- MYGN 1.3M
- NMM 119.4K
- Earning Date
- MYGN 11-06-2025
- NMM 11-04-2025
- Dividend Yield
- MYGN N/A
- NMM 0.41%
- EPS Growth
- MYGN N/A
- NMM N/A
- EPS
- MYGN N/A
- NMM 10.24
- Revenue
- MYGN $832,900,000.00
- NMM $1,305,026,000.00
- Revenue This Year
- MYGN $0.17
- NMM N/A
- Revenue Next Year
- MYGN $6.19
- NMM $7.93
- P/E Ratio
- MYGN N/A
- NMM $4.72
- Revenue Growth
- MYGN 3.83
- NMM N/A
- 52 Week Low
- MYGN $3.76
- NMM $28.37
- 52 Week High
- MYGN $29.30
- NMM $65.89
- Technical
- Relative Strength Index (RSI)
- MYGN 67.41
- NMM 64.82
- Support Level
- MYGN $7.13
- NMM $48.00
- Resistance Level
- MYGN $7.69
- NMM $49.59
- Average True Range (ATR)
- MYGN 0.43
- NMM 1.03
- MACD
- MYGN 0.03
- NMM -0.13
- Stochastic Oscillator
- MYGN 82.39
- NMM 74.55
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About NMM Navios Maritime Partners LP Common Units Representing Limited Partner Interests
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.